These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22161686)

  • 21. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
    Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
    J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
    Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
    Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys.
    Fox J; Newman MK; Turner CH; Guldberg RE; Varela A; Smith SY
    Calcif Tissue Int; 2008 Mar; 82(3):212-20. PubMed ID: 18297227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
    Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
    J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.
    Misof BM; Roschger P; Dempster DW; Zhou H; Bilezikian JP; Klaushofer K; Rubin MR
    J Bone Miner Res; 2016 Jan; 31(1):180-9. PubMed ID: 26111772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.
    Gafni RI; Guthrie LC; Kelly MH; Brillante BA; Christie CM; Reynolds JC; Yovetich NA; James R; Collins MT
    J Bone Miner Res; 2015 Nov; 30(11):2112-8. PubMed ID: 25990370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTH replacement therapy of hypoparathyroidism.
    Rejnmark L; Sikjaer T; Underbjerg L; Mosekilde L
    Osteoporos Int; 2013 May; 24(5):1529-36. PubMed ID: 23184178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.
    Fox J; Miller MA; Newman MK; Recker RR; Turner CH; Smith SY
    Bone; 2007 Sep; 41(3):321-30. PubMed ID: 17573250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased trabecular volumetric bone mass density in Familial Hypocalciuric Hypercalcemia (FHH) type 1: a cross-sectional study.
    Jakobsen NF; Rolighed L; Moser E; Nissen PH; Mosekilde L; Rejnmark L
    Calcif Tissue Int; 2014 Aug; 95(2):141-52. PubMed ID: 24894639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
    Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W
    Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
    Sosa M; Jódar E; Saavedra P; Navarro MC; Gómez de Tejada MJ; Martín A; Peña P; Gómez J
    Eur J Intern Med; 2008 Jan; 19(1):51-6. PubMed ID: 18206602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry.
    Rubin MR; Zhou H; Cusano NE; Majeed R; Omeragic B; Gomez M; Nickolas TL; Dempster DW; Bilezikian JP
    J Bone Miner Res; 2018 Nov; 33(11):1931-1939. PubMed ID: 29972871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
    Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bone changes with long term administration of low dose 1-34 human PTH on adult beagles].
    Inoue J
    Nihon Seikeigeka Gakkai Zasshi; 1985 Apr; 59(4):409-27. PubMed ID: 4031575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression.
    Tournis S; Antoniou JD; Liakou CG; Christodoulou J; Papakitsou E; Galanos A; Makris K; Marketos H; Nikopoulou S; Tzavara I; Triantafyllopoulos IK; Dontas I; Papaioannou N; Lyritis GP; Alevizaki M
    Clin Endocrinol (Oxf); 2015 Feb; 82(2):197-204. PubMed ID: 25040693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.